Preclinical characterization of ARX517, a next-generation anti-PSMA antibody drug conjugate for the treatment of metastatic castration-resistant prostate cancer

被引：2
|
作者：
Skidmore, Lillian
Mills, David
Kim, Ji Young
Shastri, Prathap
Knudsen, Nick A.
Steen, Jeff
Nelson, Jay
Buechler, Ying
Tian, Feng
Zhang, Shawn
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-3997
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3997
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Radiolabeled anti-PSMA antibody J591 immunotherapy is associated with favorable circulating tumor cell (CTC) count control in men with castration-resistant prostate cancer
    Date, Pravin
    Karir, Beerinder S.
    Batra, Jaspreet S.
    Jhanwar, Yuliya
    Beltran, Himisha
    Nanus, David M.
    Bander, Neil H.
    Tagawa, Scott T.
    CANCER RESEARCH, 2015, 75
  • [32] Re: Activity of Cabazitaxel in Castration-resistant Prostate Cancer Progressing After Docetaxel and Next-generation Endocrine Agents
    Heemers, Hannelore V.
    Mohler, James L.
    EUROPEAN UROLOGY, 2014, 66 (03) : 597 - 597
  • [33] Early PSA response is an independent prognostic factor in patients with metastatic castration-resistant prostate cancer treated with next-generation androgen pathway inhibitors
    Fuerea, Alina
    Baciarello, Giulia
    Patrikidou, Anna
    Albiges, Laurence
    Massard, Christophe
    Di Palma, Mario
    Escudier, Bernard
    Fizazi, Karim
    Loriot, Yohann
    EUROPEAN JOURNAL OF CANCER, 2016, 61 : 44 - 51
  • [34] Treatment efficacy and safety of 177Lu-PSMA Radioligand Therapy in Octogenarians with metastatic castration-resistant prostate cancer
    Langbein, T.
    Retz, M.
    D'Alessandria, C.
    Grigorascu, S.
    Hansen, K.
    Wester, H.
    Gschwend, J.
    Weber, W.
    Eiber, M.
    Tauber, R.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S132 - S133
  • [35] Can PSMA-based tumor burden predict response to docetaxel treatment in metastatic castration-resistant prostate cancer?
    Has Simsek, Duygu
    Kuyumcu, Serkan
    Karadogan, Seyfullah
    Oflas, Melis
    Isik, Emine Goknur
    Ozkan, Zeynep Gozde
    Paksoy, Nail
    Ekmekcioglu, Ozgul
    Ekenel, Meltem
    Sanli, Yasemin
    ANNALS OF NUCLEAR MEDICINE, 2021, 35 (06) : 680 - 690
  • [36] Can PSMA-based tumor burden predict response to docetaxel treatment in metastatic castration-resistant prostate cancer?
    Duygu Has Simsek
    Serkan Kuyumcu
    Seyfullah Karadogan
    Melis Oflas
    Emine Goknur Isik
    Zeynep Gozde Ozkan
    Nail Paksoy
    Ozgul Ekmekcioglu
    Meltem Ekenel
    Yasemin Sanli
    Annals of Nuclear Medicine, 2021, 35 : 680 - 690
  • [37] A phase 2 study of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in patients (pts) with progressive metastatic castration-resistant prostate cancer (mCRPC) following abiraterone and/or enzalutamide (abi/enz).
    Petrylak, Daniel Peter
    Vogelzang, Nicholas J.
    Chatta, Gurkamal S.
    Fleming, Mark T.
    Smith, David C.
    Appleman, Leonard Joseph
    Hussain, Arif
    Modiano, Manuel
    Singh, Parminder
    Tagawa, Scott T.
    Gore, Ira
    McClay, Edward Francis
    Mega, Anthony E.
    Sartor, A. Oliver
    Somer, Bradley G.
    Wadlow, Raymond Couric
    Shore, Neal D.
    Stambler, Nancy
    DiPippo, Vincent A.
    Israel, Robert Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [38] PSA flare in patients with metastatic castration-resistant prostate cancer undergoing 177Lu-PSMA treatment.
    Li, Haoran
    Wulff-Burchfield, Elizabeth Marie
    Abbasi, Saqib
    Narang, Arshit
    Dal, Emre
    Donald, Joseph
    Yap, Wendell Y.
    Shen, Xinglei
    Chen, Ronald C.
    Parikh, Rahul Atul
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 157 - 157
  • [39] Diffuse Pneumonitis after Lutetium-177-PSMA-617 Treatment in a Patient with Metastatic Castration-Resistant Prostate Cancer
    Wang, John S.
    Wong, Terence
    Wu, Kevin A.
    Mullikin, Trey C.
    Armstrong, Andrew
    BMJ CASE REPORTS, 2024, 17 (02)
  • [40] Treatment response evaluation with PSMA-PET/CT imaging in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Kleiburg, F.
    De Geus-Oei, L. F.
    Luelmo, S. A. C.
    Spijkerman, R.
    Toonen, F. A. J.
    Smit, F.
    Van der Hulle, T.
    Heijmen, L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S540 - S540
12345